Opportunity overview
Norfolk and Waveney ICB have awarded QEHKL funding to provide a Targeted Lung Cancer Screening Programme. The annual recurring costs are as follows: 1.0 WTE Band 7 £63,000 1.0 WTE Band 3 £33,000 1 PA for the responsible clinician and radiologist £14,400 This funding is recurrent to 31 March 2029, at which point this will become a national screening programme. There has been a delay in starting the programme in 2025, and it is expected that the costs for this year will be reduced accordingly In addition, there is non-recurrent funding for 0.5 PA for 6 months of £3,600. The total potential cost is £445,200, as long as the option to extend on the contract is exercised. The effective date for this modification is 11th November 2025 and the value is £445,200 to 31 March 2029. There is no change in contract dates or term which remains remains 1 April 2022 - 31 March 2030, inclusive of 3 year option to extend.
Awarded to
Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.
- Contract value
- £2.1bn
- Awarded
- Not supplied
- Contract signed
- 31 Mar 2022
- Award ID
- 025329-2026-2099 /S 001-999999-1
- Status
- active
- Identifier
- GB-NHS RCX
- Location
- Kings Lynn, UKH16, United Kingdom
Classification
- CPV85110000 — Hospital and related services
Lots
- Norfolk and Waveney ICB have awarded QEHKL funding to provide a Targeted Lung Cancer Screening Programme. The annual recurring costs are as follows: 1.0 WTE Band 7 £63,000 1.0 WTE Band 3 £33,000 1 PA for the responsible clinician and radiologist £14,400 This funding is recurrent to 31 March 2029, at which point this will become a national screening programme. There has been a delay in starting the programme in 2025, and it is expected that the costs for this year will be reduced accordingly In addition, there is non-recurrent funding for 0.5 PA for 6 months of £3,600. The total potential cost is £445,200, as long as the option to extend on the contract is exercised. The effective date for this modification is 11th November 2025 and the value is £445,200 to 31 March 2029. There is no change in contract dates or term which remains remains 1 April 2022 - 31 March 2030, inclusive of 3 year option to extend.Value not stated